Relay Therapeutics Highlights Interim Data From Bile Duct Cancer Trial
Relay Therapeutics Inc (NASDAQ:RLAY) has announced an interim data Phase 1 trial of RLY-4008 in FGFR2-altered cholangiocarcinoma (bile duct cancer) and…
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 7)
Relay Therapeutics Reports Interim Clinical Data Supporting RLY-4008 As Cholangiocarcinoma (FGFR2) Inhibitor
Interim data suggest that RLY-4008 is a highly selective FGFR2 inhibitor that has not shown to be limited by off-target toxicities of hyperphosphatemia (FGFR1) and diarrhea (FGFR4)
RLY-4008 demonstrated tumor
45 Biggest Movers From Yesterday
Gainers
Camber Energy, Inc.. (NYSE: CEI) shares surged 95.9% to close at $1.78 on Thursday after dipping over 40% on Wednesday. Camber Energy filed amended 8K showing financial statements of Viking.
Relay Therapeutics Announces Preclinical Data; Co Says Data Support RLY-2608 As First Known Allosteric Pan-Mutant Selective Inhibitor Of PI3Kα
Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today shared preclinical
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks.
5 Value Stocks In The Healthcare Sector
The Meaning Behind Value Stocks
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.
HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Lowers Price Target to $54
HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and lowers the price target from $57 to $54.
Relay Therapeutics Q2 EPS $(0.64) Misses $(0.45) Estimate, Sales $844.00K Miss $8.00M Estimate
Relay Therapeutics (NASDAQ:RLAY) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.45) by 42.22 percent. The company reported quarterly sales of $844.00 thousand which